It is generally accepted that breast cancer screening mammograms in women 50 years of age and older has saved lives. It also is generally accepted that the incidence of breast cancer in women younger than 40 is too small to warrant subjecting young women to the risks associated with mammograms. But whether women in the transition years from 40 to 49 should have routine screening mammograms has been debated for 2 decades. On January 23, the NIH Consensus Statement on Screening Mammograms for Women Ages 40 to 49 lit a powder keg when, after 2-and-a-half days of hearings and study, it announced "The data do not support a universal recommendation that all women in their 40s should undergo screening mammography." Many experts have challenged the conclusion and advocated screening mammograms every 1 to 2 years starting at age 40. To sort out the impact of the NIH statement and determine where clinicians and consumers stand, Medscape launched its first on-line survey on January 30. Most Medscape responders agree that screening mammograms every 1 to 2 years should begin at age 40 and fear that third-party health care payers will use the conclusion of the NIH consensus panel to deny reimbursement for screening mammograms in women younger than 50 years of age.

Download full-text PDF

Source

Publication Analysis

Top Keywords

screening mammograms
24
mammograms women
16
nih consensus
12
breast cancer
12
years age
12
consensus statement
8
screening
8
cancer screening
8
women
8
women 40s
8

Similar Publications

Breast cancer is one of the most aggressive types of cancer, and its early diagnosis is crucial for reducing mortality rates and ensuring timely treatment. Computer-aided diagnosis systems provide automated mammography image processing, interpretation, and grading. However, since the currently existing methods suffer from such issues as overfitting, lack of adaptability, and dependence on massive annotated datasets, the present work introduces a hybrid approach to enhance breast cancer classification accuracy.

View Article and Find Full Text PDF

Myofibroblastoma is a rare mesenchymal tumour known for its benign nature but complex diagnostic pathway. A woman in her 40s presented with a painless breast mass, initially reported as a fibroadenoma on ultrasound mammography and as a benign to borderline phyllodes tumour on fine needle aspiration cytology. Contrast-enhanced CT was reported as carcinoma of the breast with Breast Imaging and Reporting Data System (BIRADS)-6.

View Article and Find Full Text PDF

Background/objectives: Breast cancer is a significant global health concern, and early detection is crucial for improving patient outcomes. Mammography is widely used but has limitations, particularly for younger women with denser breasts. These include reduced sensitivity, false positives, and radiation risks.

View Article and Find Full Text PDF

: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as the most common chronic liver disease, is soon to be the leading indication for liver transplantation; however, the diagnosis may remain occult for decades. There is a need for biomarkers that identify patients at risk for MASLD and patients at risk for disease progression to optimize patient management and outcomes. Lymph node adiposity (LNA) is a novel marker of adiposity identified within axillary lymph nodes on screening mammography.

View Article and Find Full Text PDF

Background: Breast cancer is the most prevalent cancer among women worldwide, causing over 400,000 cases of premature death annually. Timely screening mammography (SM) could have prevented most death. Although SM utilization varies across countries, few studies have examined country-level factors, and fewer explored their interaction with individual-level factors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!